StockData
Rallybio Corp logo

Rallybio Corp (RLYB) stock

RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.26−0.03 (-0.20%)

Close on Nov 18, 2026Market cap $82.16MP/E 3.3Yield –

Rallybio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Rallybio's operating income for the twelve months ending Sep 30, 2026 was -$24.22M. For fiscal 2025 it was -$33.06M. The highest annual figure on record is -$25.30M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$33.06M–
FY2024Dec 31, 2024-$60.50M–
FY2023Dec 31, 2023-$78.93M–
FY2022Dec 31, 2022-$67.88M–
FY2021Dec 31, 2021-$45.65M–
FY2020Dec 31, 2020-$25.30M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$3.42M–
Q2 FY2026Jun 30, 2026-$5.65M–
Q1 FY2026Mar 31, 2026-$8.73M–
Q4 FY2025Dec 31, 2025-$6.41M–
Q3 FY2025Sep 30, 2025-$6.93M–
Q2 FY2025Jun 30, 2025-$10.06M–
Q1 FY2025Mar 31, 2025-$9.67M–
Q4 FY2024Dec 31, 2024-$11.61M–
Q3 FY2024Sep 30, 2024-$12.07M–
Q2 FY2024Jun 30, 2024-$17.04M–
Q1 FY2024Mar 31, 2024-$19.79M–
Q4 FY2023Dec 31, 2023-$21.11M–
Q3 FY2023Sep 30, 2023-$19.36M–
Q2 FY2023Jun 30, 2023-$20.08M–
Q1 FY2023Mar 31, 2023-$18.37M–
Q4 FY2022Dec 31, 2022-$17.09M–
Q3 FY2022Sep 30, 2022-$18.86M–
Q2 FY2022Jun 30, 2022-$17.62M–
Q1 FY2022Mar 31, 2022-$14.32M–
Q4 FY2021Dec 31, 2021-$12.31M–
Q3 FY2021Sep 30, 2021-$9.98M–
Q2 FY2021Jun 30, 2021-$10.53M–
Q1 FY2021Mar 31, 2021-$12.82M–
Q4 FY2020Dec 31, 2020-$10.09M–
Q3 FY2020Sep 30, 2020-$6.71M–
Q2 FY2020Jun 30, 2020-$4.66M–

More Rallybio figures

See a number that looks wrong?